The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Prediction of CYP2D6 phenotype from genotype across world populations
Open accessAbstract
PURPOSE: Owing to its highly polymorphic nature and major contribution to the metabolism and bioactivation of numerous clinically used drugs, CYP2D6 is one of the most extensively studied drug-metabolizing enzymes and pharmacogenes. CYP2D6 alleles confer no, decreased, normal, or increased activity and cause a wide range of activity among individuals and between populations. However, there is no standard approach to translate diplotypes into predicted phenotype. METHODS: We exploited CYP2D6 allele-frequency data that have been compiled for Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines (>60,000 subjects, 173 reports) in order to estimate genotype-predicted phenotype status across major world populations based on activity score (AS) assignments. RESULTS: Allele frequencies vary considerably across the major ethnic groups predicting poor metabolizer status (AS = 0) between 0.4 and 5.4% across world populations. The prevalence of genotypic intermediate (AS = 0.5) and normal (AS = 1, 1.5, or 2) metabolizers ranges between 0.4 and 11% and between 67 and 90%, respectively. Finally, 1 to 21% of subjects (AS >2) are predicted to have ultrarapid metabolizer status. CONCLUSIONS: This comprehensive study summarizes allele frequencies, diplotypes, and predicted phenotype across major populations, providing a rich data resource for clinicians and researchers. Challenges of phenotype prediction from genotype data are highlighted and discussed.Genet Med 19 1, 69-76.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Structure of Human Populations
Rosenberg, N. A., Pritchard, J. K., Weber, J. L., Cann, H. M., Kidd, K. K., Zhivotovsky, L. A., & Feldman, M. W. (2002) · Science · doi:10.1126/science.1078311 · Cited by 2,222
CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network
Relling, M. V., & Klein, T. E. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.279 · Cited by 1,164
Self-citationHicks, J., Bishop, Jr., Sangkuhl, K., Müller, D., Ji, Y., Leckband, S., Leeder, J., Graham, R., Chiulli, D., LLerena, A., et al. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.147 · Cited by 998
Self-citationThe CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
Self-citationPolymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part I
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318030-000000000-00000 · Cited by 756
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Klein, T. E., Caudle, K. E., Haidar, C. E., Shen, D. D., Callaghan, J. T., Sadhasivam, S., et al. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.254 · Cited by 680
Self-citationClines, Clusters, and the Effect of Study Design on the Inference of Human Population Structure
Rosenberg, N. A., Mahajan, S., Ramachandran, S., Zhao, C., Pritchard, J. K., & Feldman, M. W. (2005) · PLoS Genetics · doi:10.1371/journal.pgen.0010070 · Cited by 568
Hicks, J. K., Swen, J. J., Thorn, C. F., Sangkuhl, K., Kharasch, E. D., Ellingrod, V. L., Skaar, T. C., Müller, D. J., Gaedigk, A., & Stingl, J. C. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.2 · Cited by 453
Self-citationTemporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy
Tracy, T. S., Venkataramanan, R., Glover, D. D., & Caritis, S. N. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.08.030 · Cited by 448
Kimura, S., Umeno, M., Skoda, R. C., Meyer, U., & Gonzalez, F. J. (1989) · Europe PMC (PubMed Central) · Cited by 404
Sistonen, J., Sajantila, A., Lao, O., Corander, J., Barbujani, G., & Fuselli, S. (2007) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000239974.69464.f2 · Cited by 398
Crews, K. R., Gaedigk, A., Dunnenberger, H. M., Klein, T. E., Shen, D. D., Callaghan, J. T., Kharasch, E. D., & Skaar, T. C. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.287 · Cited by 371
Self-citationPolymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance: Part II
Zhou, S.-F. (2009) · Clinical Pharmacokinetics · doi:10.2165/11318070-000000000-00000 · Cited by 330
Isoherranen, N., & Thummel, K. E. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.050245 · Cited by 239
Complexities of CYP2D6 gene analysis and interpretation
Gaedigk, A. (2013) · International Review of Psychiatry · doi:10.3109/09540261.2013.825581 · Cited by 224
Self-citationShah, R. R., & Smith, R. L. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061093 · Cited by 197
Kalman, L., Agúndez, J., Appell, M. L., Black, J., Bell, G., Boukouvala, S., Bruckner, C., Bruford, E., Caudle, K., Coulthard, S., et al. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.280 · Cited by 178
Self-citationLLerena, A., Naranjo, M. E. G., Rodrigues‐Soares, F., Peñas‐Lledó, E., Fariñas, H., & Tarazona‐Santos, E. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.964204 · Cited by 149
Twist, G. P., Gaedigk, A., Miller, N., Farrow, E., Willig, L. K., Dinwiddie, D. L., Petrikin, J. E., Soden, S. E., Herd, S. M., Gibson, M., et al. (2016) · npj Genomic Medicine · doi:10.1038/npjgenmed.2015.7 · Cited by 132
Self-citationWang, D., Poi, M. J., Sun, X., Gaedigk, A., Leeder, J. S., & Sadée, W. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt417 · Cited by 115
Self-citationLong-Read Single Molecule Real-Time Full Gene Sequencing of Cytochrome P450-2D6
Qiao, W., Yang, Y., Sebra, R., Mendiratta, G., Gaedigk, A., Desnick, R. J., & Scott, S. A. (2015) · Human Mutation · doi:10.1002/humu.22936 · Cited by 100
Self-citationHe, Z.-X., Chen, X.-W., Zhou, Z.-W., & Zhou, S.-F. (2015) · Drug Metabolism Reviews · doi:10.3109/03602532.2015.1101131 · Cited by 78
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Ramamoorthy, A., Li, L., Gaedigk, A., Bradford, L. D., Benson, E. A., Flockhart, D. A., & Skaar, T. C. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.040329 · Cited by 71
Self-citationSingle dose, CYP2D6 genotype‐stratified pharmacokinetic study of atomoxetine in children with ADHD
Brown, J., ABDELRAHMAN, S., van Haandel, L., Gaedigk, A., Lin, Y., & Leeder, J. S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.319 · Cited by 68
Self-citationFunctional characterization of CYP2D6 enhancer polymorphisms
Wang, D., Papp, A. C., & Sun, X. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu566 · Cited by 67
Patteet, L., Haufroid, V., Kristof, M., Bernard, S., Morrens, M., & Neels, H. M. (2015) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-015-1965-1 · Cited by 65
Identification of Novel CYP2D7-2D6 Hybrids: Non-Functional and Functional Variants
Gaedigk, A., Jaime, L. K. M., Bertino, J., Bérard, A., Pratt, V. M., Bradford, L. D., & Leeder, J. S. (2010) · Frontiers in Pharmacology · doi:10.3389/fphar.2010.00121 · Cited by 60
Self-citationGaedigk, A., Fuhr, U., Johnson, C., Bérard, A., Bradford, L. D., & Leeder, J. S. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.133 · Cited by 60
Self-citationEffects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites
Byeon, J.-Y., Kim, Y., Na, H. S., Jang, J., Kim, S., Lee, Y., Bae, J., Kim, I. S., Jang, C., Chung, M. W., et al. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0646-z · Cited by 49
CYP450 Genotype and Pharmacogenetic Association Studies: a Critical Appraisal
Shah, R. R., Gaedigk, A., LLerena, A., Eichelbaum, M. F., Stingl, J., & Smith, R. L. (2016) · Pharmacogenomics · doi:10.2217/pgs.15.172 · Cited by 46
Self-citationKeller, R., Klein, M., Thomas, M., Dräger, A., Metzger, U., Templin, M. F., Joos, T. O., Thasler, W. E., Zell, A., & Zanger, U. M. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004431 · Cited by 42
Matsui, A., Azuma, J., Witcher, J. W., Long, A. J., Sauer, J., Smith, B. P., DESANTE, K. A., Read, H. A., Takahashi, M., & Nakano, M. H. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011398657 · Cited by 36
Genetic polymorphism of hepatocyte nuclear factor‐4α influences human cytochrome P450 2D6 activity†
Lee, S. S., Cha, E., Jung, H., Shon, J., Kim, E. Y., Yeo, C., & Shin, J. (2008) · Hepatology · doi:10.1002/hep.22396 · Cited by 28
Gene Copy Number Variations: It is Important to Determine which Allele is Affected
Ramamoorthy, A., & Skaar, T. C. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.5 · Cited by 28
Cited by
Zhou, Y., Ingelman‐Sundberg, M., & Lauschke, V. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.690 · Cited by 583
A Review of the Important Role of CYP2D6 in Pharmacogenomics
Taylor, C., Crosby, I., Yip, V., Maguire, P., Pirmohamed, M., & Turner, R. M. (2020) · Genes · doi:10.3390/genes11111295 · Cited by 316
Milosavljevic, F., Bukvic, N., Pavlovic, Z., Miljevic, C., Pešic, V., Molden, E., Ingelman-Sundberg, M., Leucht, S., & Jukic, M. M. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3643 · Cited by 218
Cyrius: accurate CYP2D6 genotyping using whole-genome sequencing data
Chen, X., Shen, F., Gonzaludo, N., Malhotra, A., Rogert, C., Taft, R. J., Bentley, D. R., & Eberle, M. A. (2021) · The Pharmacogenomics Journal · doi:10.1038/s41397-020-00205-5 · Cited by 95
Pharmacogenomic Biomarkers and Their Applications in Psychiatry
Kam, H., & Jeong, H. (2020) · Genes · doi:10.3390/genes11121445 · Cited by 37
Metadata
- Authors
- Gaedigk, A., Sangkuhl, K., Whirl-Carrillo, M., Klein, T., & Leeder, J. S.
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 19
- Issue
- 1
- Pages
- 69-76
- ISSN
- 1098-3600 (ISSN-L)
- OpenAlex
- W2462443690
- Cited by
- 506
- References
- 35
- FWCI
- 54.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.